P14.15 Benefit of Bevacizumab for recurrent glioblastoma. Results of 81 patients from a single institution

BACKGROUND: No standard of care has been established for patients with progressive glioblastoma (rGBM). Previous studies suggested that bevacizumab (BEV) is safe and produces responses that result in a decreased use of glucocorticoids and increased progression-free survival (PFS) with an unclear eff...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Neuro Oncol
Autors principals: Absalyamova, O, Kobiakov, G, Agabekyan, G, Poddubsky, A, Belyashova, A, Lodygina, K, Absalyamov, A, Kobiakov, N
Format: Artigo
Idioma:Inglês
Publicat: Oxford University Press 2019
Matèries:
Poster Presentations
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC6795927/
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/neuonc/noz126.250
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars